Results 181 to 190 of about 1,091,889 (296)

Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency. [PDF]

open access: yesTher Innov Regul Sci, 2023
Ayalew K   +11 more
europepmc   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

open access: yesMolecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski   +12 more
wiley   +1 more source

Is Good Clinical Practice Becoming Poor Clinical Care?

open access: yesHemaSphere, 2017
Steven Le Gouill   +16 more
doaj   +1 more source

ISP Good Clinical Practice Recommendations for the management of Dentin Hypersensitivity.

open access: yesJ Indian Soc Periodontol, 2022
Grover V   +29 more
europepmc   +1 more source

FIGO good clinical practice paper: management of the second stage of labor. [PDF]

open access: yesInt J Gynaecol Obstet, 2021
Wright A   +5 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

The new Good Clinical Practice-2020 in China: Views from ethical perspective. [PDF]

open access: yesLancet Reg Health West Pac, 2021
Yang F, Heng J, Li K, Wang J.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy